



8th International congress mage by the set of the se

Results of two clinical trials in vulnerable populations support the evaluation of BIO101 (20-hydroxyecdysone), a MAS Receptor activator as a candidate oral treatment for rare pediatric neuromuscular diseases

Cendrine Tourette¹, Waly Dioh¹, Sandrine Rabut¹, Serge Camelo¹, Jean Mariani^{1,2}, Rob Van Maanen¹, Stanislas Veillet¹

1. Biophytis, Sorbonne University, 75005 Paris, France; 2. Sorbonne Université, CNRS - Institute de Biologie Paris Seine (UMR B2A), 75005 Paris, France


BIO101 (20-Hydroxyecdysone - 20E)


BIO101 (20-hydroxyecdysone – 20E) is a <u>new oral drug candidate</u> activating the MAS receptor (a major receptor in the renin-angiotensin system) leading to muscle anabolism, which already demonstrated meaningful activity in animal models of muscular dystrophies (Lafont *et al.*, 2022) and respiratory function. Furthermore, BIO101 (20E) has also demonstrated beneficial effects in two vulnerable populations in clinical settings, in the COVA and SARA-INT trials.

Duchenne Muscular Dystrophy Preclinical Data on respiratory function in mdx mice

- Whole body Plethysmography

8_Γ -⊡ C57B10






BIO101 (20E) is a pharmaceutical grade preparation of 20-hydroxyecdysone. BIO101 is a MASR activator


J Mol Endocrinol. 2021 Dec 23;68(2):77-87. doi: 10.1530/JME-21-0033.

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor

René Lafont ¹², Maria Serova ¹, Blaise Didry-Barca ¹, Sophie Raynal ¹, Louis Guibout ¹, Laurence Dinan ¹, Stanislas Veillet ¹, Mathilde Latil ¹, Waly Dioh ¹, Pierre J Dilda ¹ Affiliations + expand PMID: 34825653 DOI: 10.1530/JME-21-0033



Sustainable 20E (BIO101) effects on lung reactivity in C57B10 mdx mice. The enhanced pause (Penh) of mdx, BIO101 treated mdx mice, and WT C57B10 was measured in response to 40 mg/ml of methacholine by plethysmography *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Bonferroni test compared to control at each time point.



 BIO101 treatment significantly improves airway responsiveness as measured by PenH (normalization of Penh values in mdx mice vs control mice).
 BIO101 effects are sustained for 6 months.

> For full preclinical proof of concept, see **Poster #P083**

SARA-INT trial

0.1

233 Sarcopenic seniors aged 65+ (FNIH criteria + SPPB ≤8) treated with BIO101 at 2 doses (175 mg / 350 mg bid BIO101 versus placebo) up to 9 months

Secondary statistical analysis of Change From Baseline (CFB) in 400MWT gait speed based on Multiple Imputation for subjects without on-site visit data at M6 and adjusted Bayesian Imputation for non completers at M6 in the FAS population

LS mean change from baseline in 400MWT gait speed (m/s)

COVA trial

233 hospitalized patients with severe COVID-19 having signs of pneumonia who may or may not require oxygen supplementation, and who are not on invasive mechanical ventilation or ECMO (extracorporeal membrane oxygenation), treated with BIO101 350 mg bid (n=126) versus placebo (n=107) up to 28 days.

KM analysis in the ITT population showed a difference in proportion of patients with respiratory failure or early death between BIO101 and placebo, p=0.0223, with a reduction of 43% in the treatment arm.


death in BIO101 group versus placebo, CMH test, <u>p=0.0426</u>, with a relative risk reduction

> Trend in the adjusted difference in the proportion of patients with hospital discharge of

11% in BIO101 group versus placebo in ITT population, p= 0.0586 – CMH test

Time to respiratory failure or early death at day 28

₩ 10-




- > Natural deterioration in gait speed in placebo group, comparable to <u>OBS</u>ervational study
- Trend for a dose effect
- Close to statistical significance and close to clinical significance at the highest dose, consistent with other physical assessments

BIO101 (20E) safety profile



- In the SARA-INT trial, BIO101 (20E) showed a good safety profile after up to 9 months of dosing, with no significant difference between treatment arms and placebo for TEAEs, related TEAEs and SAEs as well as biliary imaging studies, ECG, safety laboratory parameters and vital signs.
- The COVA study showed a lower proportion of patients with TEAEs in the BIO101 350 mg bid group than in the placebo group (57% vs 64.4%) and in particular, a lower frequency for serious respiratory TEAEs (25% vs 30.8%).



of respiratory failure or early death of 43.8%

Reduction in the relative risk of early death by 43.8% at day 90

MYODA proposed trial design

Proposed Trial design	Study Endpoints	Patient Population
 A Randomized, Double-Blind, multi-center Phase 1-2 Study Approximately 12 clinical centers US/EU Evaluation of the Safety, PK, PD and Efficacy of BIO101 in Non-Ambulatory DMD Patients with Respiratory Deterioration Pediatric oral formulation (powder suspension) of BIO101 	 Part 1 (N=15): Safety, tolerability & PK- initial 7 days of dosing of escalating dose of BIO101 (1.25 up to 4 mg/kg) Part 2 (N=30 + 15 from Part1): Efficacy of BIO101 - Respiratory function after treatment for 48 weeks Endpoints: respiratory function (FVC, PEF), muscle strength (PUL, Myogrip), QoL questionnaires 	 Age: ≥12 years old Non-ambulatory DMD patients, regardless of the genetic mutation Patients with respiratory failure not yet requiring mechanical ventilation

> BIO101 (20E) is a promising oral treatment for DMD patients with respiratory deterioration.

- > Beneficial effects on motor function in sarcopenic patients (SARA-INT phase 2b) and beneficial effects on COVID-19 patients with respiratory failure (COVA phase 2/3)
- > Favorable safety profile (SARA-PK phase 1, good safety data on 149 SARA-INT participants with at least 6 Months of treatment and 126 adults in the COVA study)
- > ODD granted in Europe and US, Biophytis plans to start the Phase 1/2 MYODA clinical trial after last regulatory interactions.